ChemoCentryx - Product Pipeline - CCR9 Program - PROTECT-1 Clinical Trial
... in Crohn's disease Trial (PROTECT-1) is designed to demonstrate Traficet-EN™'s ... 250 mg once daily, 500 mg once daily or 250 mg twice daily of Traficet-EN. ...ChemoCentryx - News - Press Releases
The agreement encompasses Traficet-EN, a specific CCR9 antagonist currently in a ... Traficet-EN is intended to control the inappropriate inflammatory response ...ChemoCentryx Presents Positive Results from Phase 1 Clinical Studies of ...
ChemoCentryx Presents Positive Results from Phase 1 Clinical Studies of Traficet - CHICAGO -- ChemoCentryx, Inc. presented positive Phase 1 clinical and : ...PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryx's ...
Oral CCR9 Antagonist Demonstrates Clinical Efficacy with Favorable Tolerability ... C-reactive protein (CRP) results confirmed the effect of 500 mg QD Traficet-EN. ...GlaxoSmithKline and ChemoCentryx enter into drug discovery and ...
not named ... The agreement encompasses Traficet-EN®, a specific CCR9 antagonist currently in ... Traficet-EN®is intended to control the inappropriate ...ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical ...
LifeSciencesWorld is your online resource for biotechnology, pharmaceutical, ... Traficet-EN is an orally-active inhibitor of the chemokine receptor known as ...